Asciminib
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Conditions
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Trial Timeline
Nov 28, 2024 → Nov 1, 2026
NCT ID
NCT06427811About Asciminib
Asciminib is a approved stage product being developed by Novartis for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase. The current trial status is active. This product is registered under clinical trial identifier NCT06427811. Target conditions include Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04360005 | Pre-clinical | Active |
| NCT07250087 | Phase 1 | Recruiting |
| NCT06629584 | Phase 2 | Recruiting |
| NCT06427811 | Approved | Active |
| NCT06236724 | Phase 2 | Recruiting |
| NCT05384587 | Phase 2 | Active |
| NCT04795427 | Phase 2 | Completed |
| NCT03605277 | Phase 1 | Completed |
Competing Products
20 competing products in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imatinib Mesylate | Novartis | Phase 2 | 52 |
| Nilotinib | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 3 | 77 |
| STI571 400 mg + STI571 600 mg | Novartis | Phase 2 | 52 |
| Induction Phase + Re-Induction Phase + Post-Remission + Maintenance | Novartis | Phase 2 | 52 |
| nilotinib | Novartis | Phase 2 | 52 |
| Asciminib + Nilotinib | Novartis | Phase 3 | 77 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Blinatumomab + Asciminib | Novartis | Phase 1/2 | 41 |
| Asciminib | Novartis | Phase 1 | 33 |
| Asciminib Pediatric formulation group + Asciminib Adult formulation group | Novartis | Phase 1/2 | 41 |
| Nilotinib + LDE225 | Novartis | Phase 1 | 33 |
| Nilotinib | Novartis | Approved | 85 |
| Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib | Novartis | Phase 3 | 77 |
| Blinatumomab | Amgen | Phase 2 | 51 |
| Treatment with blinatumomab given subcutaneously. | Amgen | Phase 2 | 51 |
| Blinatumomab + Blinatumomab + HyperCVAD | Amgen | Phase 3 | 76 |
| Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen | Amgen | Phase 3 | 76 |
| Bosutinib | Pfizer | Phase 1/2 | 40 |
| Bosutinib + Bosutinib | Pfizer | Phase 1 | 32 |